The purpose of this study is to assess the safety of treatment with the investigational drug CC-92480 in combination with dexamethasone for patients with multiple myeloma that has come back or continued to grow despite standard therapy. CC-92480 is a type of drug called a "cereblon-modifying (CM) agent."
Other CM agents used to treat multiple myeloma include thalidomide, lenalidomide, and pomalidomide. CC-92480 is a new CM agent that is thought to be more effective for targeting and destroying proteins that help to produce myeloma cells. The effect of CC-92480 may be increased when it is used in combination with dexamethasone, a standard part of myeloma treatment. Both CC-92480 and dexamethasone are taken orally (by mouth).
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
The following is a listing of trial locations that are open and accepting patients.
The following is a listing of trial locations that are not currently open and accepting patients.
June 01, 2020
There are no resources, links or videos to display for this clinical trial.